Introduction
Methods
Search strategy
Study |
N
| Gene | Mutationa | AAOa | AADa | Targeta | LP | PRE-UPDRS IIIa | POST-UPDRS IIIa | %b | FU | NOS | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Healy et al. [9] | 18 |
LRRK2
| p.G2019S | NA | NAA | STNc | NA | NA | NA | NA | NA | 4 | Good or excellent (n = 8), moderate (n = 2), poor (n = 2) and NA (n = 6) |
Sayad et al. [16] | 15 |
LRRK2
| p.G2019S | 40.1 ± 9.4 | NA | STN bilat. | + | 55.8 ± 16.4 M−, 25.0 ± 13.2 M+ (NC: 51.7 ± 14.4 M−) | 27.3 ± 20.6 M−S+, 19.7 ± 18.8 M+S+ (NC: 38.5 ± 16.6 M−S+) | 51.1 (NC: 25.5) | 2 | 10 | Favourable and better outcome compared to patients without mutation |
Greenbaum et al. [17] | 13 |
LRRK2
| p.G2019S | 49.5 ± 6.8 | 61.1 ± 6.6 | STN bilat. | + | 42.5 ± 11.8 M−, 19.5 ± 13 M+ (NC: 43.4 ± 12.3 M−) | Short FU 28.5 ± 13.1 M−S+, 17.4 ± 12.9 M+S+ Long FU 30.5 ± 12.8 M−S+, 21.2 ± 9.2 M+S+ (NC: Short FU 27.2 ± 14.1 M−S+, Long FU 33.9 ± 16.1 M−S+) | Short FU 32.8 ± 31.1 Long FU 28.5 ± 32.9 (NC: Short FU 35.6 ± 25.3, Long FU 17 ± 37.1) | 0.5–1 (n = 13), 3 (n = 11) | 10 | Favourable and comparable to patients without mutations. One patient reported new/worse psychiatric symptoms at 3-year follow-up |
Schüpbach et al. [18] | 9 |
LRRK2
| p.G2019S (n = 7) p.G2019S + het. PRKN mutation (n = 1), p.T2031S (n = 1) | 33–48 | 38–65 | STN bilat. | NA | 41.4 ± 12.4 M−, 8.2 ± 4.6 M+ (NC: 43.4 ± 17.0 M−) | 47.7 ± 13.1 M−S−, 17.8 ± 9.6 M−S+, 11.8 ± 4.5 M+S−, 6.2 ± 3.9 M+S+ (NC: 15.7 ± 9.0) | 50 ± 36 (NC: 64) | 9–10 (Long-term FU for two patients) | 10 | Favourable and comparable to patients without mutations, but cognitive, behavioral and psychotic problems in the patient with p.T2031S mutation after 5 years |
Pal et al. [19] | 5 |
LRRK2
| NA | 47.5 ± 11.0 (n = 4) | 60.8 ± 9.0 (n = 4) | NA | NA | NA | 30.8 ± 11.7 M+S+ (n = 4) | NA | 3.5 ± 2.4 (n = 4) | 6 | The outcome is not reported. Clinical data before DBS is not available, but UPDRS III score was higher in LRRK2 -patients compared to patients without mutations at follow-up |
Angeli et al. [15] | 5 |
LRRK2
| p.G2019S (n = 4), p.G2019S + GBA-E326K (n = 1) | 35–55 | NAB | STNc | NA | 65.4 ± 14.9 M−, 10.8 ± 5.1 M+ (NC: 47.6 ± 14.8 M−) | 69.2 ± 12.4 M−S−, 30.6 ± 16.1 M−S+ (24.6 ± 11.3 M−S+) | 53 (NC: 48) | 1–5 | 9 | Favourable and comparable to patients without mutations. No reported cognitive problems |
Gómez-Esteban et al. [20] | 4 |
LRRK2
| p.R1441G | 29–55 | 41–65 | STN bilat. | + | 48.5 ± 18.5 M−, 18.0 ± 7.4 M+ (NC: 42.5 ± 10.6 M−) | 39.7 ± 17.7 M−S+, 16.0 ±/–7.7 M+S+ (NC: 26.1 ± 8.4 M−S+) | 18 (NC: 39) | 0.5 | 10 | Poorer response compared to patients without mutation |
Johansen et al. [21] | 3 |
LRRK2
| p.G2019S | 43–57 | 50–69 | STN bilat. | + | NA for individual genes (NC: 35.7 ± 6.7 M−) | NA for individual genes (NC: 19.7 ± 5.5 M−S+) | NA (NC: 44.8) | 5 | 9 | Favourable and comparable to patients without mutations |
Lesage et al. [22] | 3 |
LRRK2
| p.G2019S (n = 2), p.T2031S (n = 1) | 34–45 | 41–66 | STNc | NA | 14 M+ (n = 1), NA (n = 2) | 27 M−S+ (n = 1), 17 M−S+ and 32 M−S− (n = 1) | NA | 7 (Long-term FU for one patient) | 9 | Favourable to motor symptoms, but depression and psychosis in the patient with p.T2031S mutation |
Gaig et al. [23] | 3 |
LRRK2
| p.G2019S | 33–62 | NA | STN bilat. | NA | NA | NA | NA | NA | 5 | Favourable to motor symptoms |
Goldwurm et al. [24] | 3 |
LRRK2
| p.G2019S | NA | NA | NA | NA | NA | NA | NA | NA | 2 | NA |
Hatano et al. [25] | 1 |
LRRK2
| p.R1441G and p.G2385R | 28 | 39 | STN bilat. | + | NA | NA | NA | 2 | 7 | Poor motor response with severe psychiatric problems at 1 year after operation |
Stefani et al. [26] | 1 |
LRRK2
| Het. p.G2019S | 49 | 56 | STN bilat. | + | 27 M−, 12 M+ | 25 M−S−, 8 M−S+, 5 M+S+ | 70.4 | 0.25 | 8 | Favourable outcome |
Puschmann et al. [27] | 1 |
LRRK2
| p.N1437H (c.4309A > C) | 50 | 69 | STN bilat. | + | NA | 65 M−S+ | NA | 0.5 | 8 | Poor motor outcome. Patient had also severe depression and suicidality and she finally committed suicide 6.5 months after DBS implantation |
Perju-Dumprava et al. [28] | 1 |
LRRK2
| p.Y1699C | 43 | 48 | STN bilat. | NA | 54 M−, 32 M+ | 26 M−S+, 15 M+S+ | 52 M−, 53 M+ | 2.5 | 10 | Favourable outcome. No changes in neuropsychological test parameters 6 months postoperatively |
Breit et al. [29] | 1 |
LRRK2
| p.R793M | 42 | 60 | STN bilat. | NA | NA | NA | 64 (1 year), 56 (8 year) | 8 | 8 | Favourable outcome |
Aasly et al. [30] | 1 |
LRRK2
| p.Asn1437His | NA | NA | STNc | NA | NA | NA | NA | NA | 4 | Favourable outcome |
Lohmann et al. [31] | 14 |
PRKN
| One mutation: ex6hetdupl, ex6hetdel, Arg256Cyshet [n = 2], Ala398Thrhet, ex7hetdupl, and exhet3del; Hom. or compound het.: ex5hetdel—c.255delAhet, ex3hetdel—prom-ex1hetdel, ex2-4hetdupl—ex3hetdel, Cys289Glyhom, ex5hetdel—Cys441Arghet, ex2hetdel—ex3hetdel and ex4-7hetdel—IVS7-1GC | 14–52 | 32–67 | STN bilat. | NA | One mutation 54.3 ± 13.9 M−, 11.6 ± 12.7 M+ Two mutations 55.4 ± 17.3 M−, 14.5 ± 10 M+ (NC: 51.9 ± 18.3 M−) | One mutation 38.4 ± 16.8 M−S− 12.7 ± 11.2 M+S−, 17.8 ± 11.2 M−S+, 10.8 ± 10.1 M + S+ Two mutations 47.7 ± 12.8 M−S−, 17 ± 10.9 M−S+, 14.5 ± 12.5 M−S+, 9.3 ± 8.6 M+S+ (NC: 17.9 ± 15.1 M−S+) | One mutation 69 ± 15 Two mutations 77 ± 14 (MC: 65.5) | 1–2 except 3 years for one patient with two PRKN mutations | 10 | Motor response was favourable and comparable to patients without mutations, but more cognitive problems in homozygous and compound heterozygous patients compared to patients without mutations |
Moro et al. [32] | 11 |
PRKN
| One mutation: delEx6, duplEx5, 867C > T, 1306G > C, delEx5-12; Hom. or compound het.: 202delA [n = 2], delEx3-4, delEx3 + 1142-3delGA, delEx2-5 + duplEx8, delEx7-9 | 15–40 | 31–66 | STN bilat. | NA | 35–66 (MV = 49.5) | NA | Short FU 36 Long FU 42 (NC: Short FU 56, Long FU 44) | 3–6 | 9 | Favourable and comparable to patients without mutations in long-term follow-up |
Pal et al. [19] | 10 |
PRKN
| NA | 30.6 ± 9.1 | 47.0 ± 11.5 | NA | NA | NA | 33.8 ± 20.5 M+S+ (n = 6) | NA | 4.0 ± 4.2 | 6 | The outcome is not reported. Clinical data before DBS is not available but UPDRS III score was higher in PRKN -patients compared to patients without mutations at follow-up |
Angeli et al. [15] | 5 |
PRKN
| Hom.: c.101_102delAG, c.1289G > A p.G430D and c.823C > T, p.Arg275Trp, c.337_376del and c.465–466del, Hom. deletion of exon 3 and 4, c.823C > T; p.Arg275Trp and het. duplication of exon 6 | 7–36 | NAB | GPi (n = 3), STNc (n = 2) | NA | All 57.0 ± 11.2 M−, 21.0 ± 6.4 M+ GPi 53.3 ± 13.9 M− STN 62.5 ± 3.5 M− (NC: STN: 47.6 ± 14.8 M−GPi: 40.5 ± 13.4 M−) | GPi 43.3 ± 16.4 M−S− 42.0 ± 19.0 M−S+ 27.3 ± 17.6 M+S+ STN 84.0 ± 22.6 M-S− 43.0 ± 0.0 M-S+ 23.5 ± 6.4 M+S+ (NC: STN: 24.6 ± 11.3 M-S+, GPi: 51.0 ± 7.1 M-S+) | GPi 21 STN 31 (NC: STN: 48, GPi: − 28) | 1–5 | 9 | Good to motor symptoms without cognitive problems. The percentage improvement in the UPDRS III score was better with STN-DBS than with GPi-DBS |
Romito et al. [11] | 5 |
PRKN
| G828A and Dupl ex1, DelAG 202-203, C1101T, G535A, Dupl ex1 | 27–45 | 42–63 | STN bilat. | + | 57.3 ± 9.3 M− 22.8 ± 7.3 M+ (NC: 59.7 ± 11.3 M−) | 25.2 ± 10.0 M−S+ 21.8 ± 7.5 M+S+ (NC: 29.0 ± 12.3 M−S+) | 56 (NC: 51.4) | 1–3 | 10 | Favourable and comparable to patients without mutations |
Johansen et al. [21] | 4 |
PRKN
| Het. c.delEx3, Het. p.R275W, Het. c.duplEx7, Hom. c.delEx5 (GPi) | 35–46 | 50–59 | STN bilat. (n = 3), GPi unilat. (n = 1) | + | NA for individual genes (NC: 35.7 ± 6.7 M−) | NA for individual genes (NC: 19.7 ± 5.5 M−S+) | NA (NC: 44.8) | 5–7 | 9 | Favourable and comparable to patients without mutations |
Kim et al. [33] | 3 |
PRKN
| NA | 21.7 ± 8.5 | 49.7 ± 16.2 | STN bilat. | NA | 49.8 ± 24.5 M−, 18.3 ± 7.8 M+ (NC: 38.3 ± 10.6 M−) | 24.7 ± 14.0 M−S+, 22.2 ± 14.9 M+S+ (NC: 17.2 ± 5.5 M−S+) | 37.1 ± 45.4 (NC: 54.6 ± 13.9) | 2–5 | 10 | Favourable and comparable to patients without mutations |
Hassin-Baer et al. [34] | 3 |
PRKN
| Hom. 202 A deletion | 15–28 | 31–54 | STNc | NA | 27–64 M−, 20–48 M+ | NA | NA | NA | 7 | Modest outcome with improvement in appendicular symptoms, but no change in axial features |
Sayad et al. [16] | 2 |
PRKN
| Het. c. 458C > G | 48 | NA | STN bilat. | + | 46 M−, 28 M+ | 51 M−S+, 30 M+S+ | − 10.1 | 2 | 10 | Poor response |
Het. c. 1204C > T | 48 | + | 49 M−, 32 M+ (NC: 51.7 ± 14.4 M−) | 51 M−S+, 47 M+S+ (NC: 38.5 ± 16.6 M−S+) | − 4.1 (NC: 25.5) | ||||||||
Thompson et al. [35] | 2 |
PRKN
| Hom., specific mutation NA | 26 (Gpi), 30 (STN) | NA | STN bilat. (n = 1), GPi bilat. (n = 1) | NA | GPi 57 M−, 50 M+ STN 47 M−, 21 M+ | NA | NA | 3 (STN), 8 (GPi) | 6 | Favourable outcome |
Genç et al. [36] | 1 |
PRKN
| Het. c89G > A and large het. deletion | 10 | NA | STN bilat. | + | 48 M−, 7 M+ | 7 M−S+, 4 M+S+ | 85.4 | NA | 6 | Favourable to motor symptoms |
Moll et al. [37] | 1 |
PRKN
| Compound het. PRKN mutation (delExon1 + c.924C > T) | 35 | 45 | STN bilat. | + | 30 M− 5 M+ | NA | NA | NA | 7 | Favourable to motor symptoms |
Nakahara et al. [38] | 1 | PRKN + PINK1 | Hom. parkin mutation (p.T175PfsX2) + het. PINK1 mutation (p.R58-V59insGR) | 15 | 60 | STN bilat. | + | 86 M−, 25 M+ | 33 M−S+, 21 M+S+ | 62 | 0.7 | 9 | Favourable outcome |
Lefaucheur et al. [39] | 1 |
PRKN
| Compound het. mutations of the PRKN gene, [c.101_102delAG (p.Gln34ArgfsX5) + c.155delA (p.Asn52MetfsX29)] | 25 | 69 | STNc | NA | NA | NA | 55 | 0.5 | 8 | Favourable to motor symptoms without cognitive problems |
Wickremaratchi et al. [40] | 1 |
PRKN
| Compound het. exon 2/exon 2 1 3 deletion in the PRKN | 8 | 46 | Zona incerta bilat. | NA | 68 M−, 22 M+ | NA M−S+ 24 M+S+ | NA M−, 64.7 M+ | 0.5 | 9 | Favourable outcome |
Lesage et al. [41] | 1 |
PRKN
| Compound het. of the PRKN c.1-?_7+?del and c.172-?_412+?del mutations | 8 | 39 | STN bilat. | NA | 46 M−, 15.5 M+ | NA | NA | NA | 6 | Favourable outcome |
Capecci et al. [42] | 1 |
PRKN
| Hom. deletion in exon 3 | 22 | NA | STN bilat. | + | 45 M−, 5 M+ | 7 M−S+, 3 M+S+ | 84.4 | 1 | 8 | Favourable outcome |
Khan et al. [43] | 1 |
PRKN
| Exon 9 1101C–>T (Arg334Cys), exon 7 939G–>A (Asp230Asn) | 30 | 35 | STN bilat. | NA | NA | NA | NA | NA | 6 | Favourable outcome |
Lythe et al. [14] | 17d |
GBA
| Het. mutation carriers (n = 15), hom. mutation carrier (n = 1), compound het. (n = 1). Two patients also carried a mutation in another PD-associated gene; PARKIN or LRRK2 | 41.4 ± 5.8 | 53.5 ± 4.5 | STNc (n = 15), GPi (n = 2) | NA | 52.4 ± 13.0 M−, 18.4 ± 14.9 M+ (NC: 40.5 ± 12.0 M−) | NA M−S+, 50.0 ± 17.1 M+S+ (n = 9) (NC: NA M−S+, 38.9 ± 14.0 M+S+) | 4.6 M+S+ (n = 9) (NC: 4.0 M+S+) | 7.5 (n = 9) | 9 | Follow-up data available for 9 patients. Poorer outcome compared to patients without mutations. GBA mutation carriers had faster rate of cognitive decline, reported significantly worse quality of life and exhibited a greater burden of non-motor symptoms compared to patients without mutations. During follow-up 3 GBA + patients were deceased, 2 were unable to complete follow-up due to severe PD-related disability, 2 could not be contacted and 1 DBS hardware was removed |
Angeli et al. [15] | 16 |
GBA
| R463C/R463C, L444P/E326K, N370S, D409H, recNcil, R463C, N188S, R275Q, IVS2 + 1 G > A, L444P, E326K/E326K, E326K (n = 3), E326K and LRRK2 p.G2019S, T369M and PRKN c.1310C > T | 34–58 | NAB | STNc (n = 13), GPi (n = 2), VIM (n = 1) | NA | All 51.3 ± 14.0 M−, 18.0 ± 15.4M+ GPi 64.5 ± 21.9M− STN 50.5 ± 12.4 M− VIM 35 M− (NC: STN: 47.6 ± 14.8 M−GPi: 40.5 ± 13.4 M−) | GPi 66.5 ± 19.1 M−S−, 50.0 ± 19.8 M−S+, 41.0 ± 15.6 M+S+ STN 56.1 ± 18.8 M−S−, 28 ± 11.4 M−S+, 15.9 ± 10.4 M+S+ VIM 35 M−S−, 20 M−S+, 8 M+S+ (NC: STN: 24.6 ± 11.3 M−S+ GPi: 51.0 ± 7.1 M−S+) | GPi 22 STN 40 VIM 43 (NC: STN: 48, GPi: − 28) | 1–5 | 9 | Favourable motor response, but faster rate of cognitive decline compared to patients without mutations. The percentage improvement in the UPDRS III score “OFF- medication” was better with bilateral STN-DBS and VIM-DBS than with GPi-DBS |
Pal et al. [19] | 12 |
GBA
| p.N370S (n = 8), p.L444P (n = 3). 1 patient carried both GBA and LRRK2 mutations and was excluded | 41.6 ± 5.3 (n = 11) | 53.9 ± 2.6 (n = 9) | NA | NA | NA | 27.4 ± 14.5 M+S+ (n = 11) | NA | 1.6 ± 3.0 (n = 9) | 6 | The outcome is not reported. Clinical data before DBS is not available, but UPDRS-III score was little higher in GBA -patients compared to patients without mutations at follow-up |
Weiss et al. [44] | 3 |
GBA
| p.N370S (n = 1) and p.L444P (n = 2) | 47–54 | 65–69 | STNc | NA | 26 and 53 M−, 14 and 19 M+, NA (n = 1) (NC: 31–63 M−) | 56–71 M−S−, 21–45 M−S+, 32–48 M+S−, 20–45 M+S+ (NC: 21–42 M−S+) | 30–75 (NC: 22–54) | 6–10 | 11 | Favourable outcome, but substantial increase of axial motor impairment in the long-term with declining therapeutic response in GBA carriers. GBA carriers developed also a significant cognitive impairment |
Lesage et al. [45] | 2 |
GBA
| Hom. p.N370S | 52 | NA | STN bilat. | NA | NA | NA | NA | NA | 5 | Favourable outcome |
c.1263del + RecTL | 21 | 24 | 2 | Some clinical benefit 2 years after DBS, but problems with postural instability | |||||||||
Martikainen et al. [46] | 1 |
SNCA
| Het. c.158C > A (p.A53E) | 42 | 46 | STN bilat. | NA | 31 M−, 8 M+ | NA | NA | 3.5 | 9 | Favourable motor outcome in the short-term but poor in the long-term follow-up. Response for motor fluctuations remained satisfactory but the cognitive and mental state of the patient deteriorated to a state of practical immobility |
Perandones et al. [47] | 1 |
SNCA
| SNCA duplication | 18 | 26 | GPi bilat. | + | NA | NA | NA | 0.1 | 6 | Favourable and comparable to patients without mutations |
Shimo et al. [48] | 1 |
SNCA
| SNCA duplication | 35 | 41 | STN bilat. | + | 27 M−, 10 M+ | 13 M−S+ | 51.9 | 4 | 9 | Favourable motor outcome without cognitive or psychiatric problems |
Antonini et al. [49] | 1 |
SNCA
| SNCA duplication at 4q22.1 | 41 | 46 | STN bilat. | + | 28 M−, 10 M+ | 16 M−S+, 10 M+S+ | 42.9 | 2 | 9 | Favourable outcome in short-term follow-up but patient developed visual hallucinations and cognitive deterioration and died two years after operation due to metastatic breast cancer |
Ahn et al. [50] | 1 |
SNCA
| SNCA duplication | 40 | 46 | STN bilat. | NA | 32 M−, 6 M+ | NA | NA | NA | 6 | Excellent motor response but later patient’s dementia worsened, requiring assistance in daily activities |
Fleury et al. [51] | 2 |
VPS35
| p.D620N | 49 | 60 | STN bilat. | NA | 58 M−, 17 M+ | 32 M−S−, 18 M−S+, 18 M+S−, 15 M+S+ | 76 (1 year) 69 (8 years) | 8 | 8 | Favourable outcome |
45 | 55 | 28 M−, 15 M+ | NA | 36 (1 year) | 1 | Tremor, akinesia and rigidity improved markedly but patient’s walking difficulties worsened with an increased frequency of freezing episodes and falls after surgery (problems disappeared after levodopa intake with the STN-DBS switched on) | |||||||
Chen et al. [52] | 1 |
VPS35
| p.D620N | 42 | 55 | STN bilat. | + | 42 M−, 15 M+ | 35 M−S−, 22 M−S+, 15 M+S−, 13 M+S+ | 37 | 5 | 9 | Favourable outcome |
Kumar et al. [53] | 1 |
VPS35
| p.D620N | NA | NA | NA | NA | NA | NA | NA | NA | 3 | Little benefit to motor symptoms, but patient developed significant dysarthria |
Sheerin et al. [54] | 1 |
VPS35
| p.D620N | 47 | NA | NA | NA | NA | NA | NA | NA | 5 | Favourable outcome. No reported cognitive problems |
Borellini et al. [55] | 1 |
PINK1
| Hom. L347P | 30 | 49 | GPi | NA | 44 M− | 32 M + S+ | 27 | 0.1 | 7 | Moderate outcome |
Nakahara et al. [38] | 1 | PRKN + PINK1 | Hom. parkin mutation (p.T175PfsX2) + het. PINK1 mutation (p.R58-V59insGR) | 15 | 60 | STN bilat. | + | 86 M−, 25 M+ | 33 M−S+, 21 M + S+ | 62 | 0.7 | 9 | Favourable outcome |
Johansen et al. [21] | 1 |
PINK1
| Het. p.G411S | 50 | 59 | STN bilat. | + | NA for individual genes (NC: 35.7 ± 6.7 M−) | NA for individual genes (NC: 19.7 ± 5.5 M−S+) | NA (NC: 44.8) | 5 | 9 | Favourable and comparable to patients without mutations |
Moro et al. [32] | 1 |
PINK1
| Hom. c.509T > G (p.V170G) | 31 | 61 | STN bilat. | NA | 35.5 M− | NA | Short FU 46.5 Long FU 43.7 (NC: Short FU 56, Long FU 44) | 3–6 | 9 | Favourable and comparable to patients without mutations |
Valente et al. [56] | 1 |
PINK1
| NA | NA | NA | STN bilat. | NA | NA | NA | NA | NA | 3 | Motor outcome was not properly reported but patient developed imbalance, gait impairment, dysarthria, and behavioral changes at the age of 54 years. Mental deterioration was documented a few years later |
Dufournet et al. [57] | 3 | 22q11.2 Del. Syndrome | 34–38e | NA | STNc (n = 1) GPi (n = 2) | NA | NA | NA | 30–70 | NA | 7 | Favourable and comparable to patients with idiopathic PD |
Gene | Studies (n) | Patients (n) | Target | Outcome |
---|---|---|---|---|
LRRK2
| 17 | 87a | STN: n = 79 (90.8%) NA: n = 8 (9.2%) | Mostly favourable motor outcome. Four studies with eight patients (9.2%) reported poor motor outcomes and one study reported moderate outcomes for two patients. Both patients with the LRRK2 p.T2031S (c.6091A > T) mutation (n = 2) developed neuropsychiatric problems 5–7 years after implantation. The outcome appears poor in patients with LRRK2 p.R1441G (c.4321C > G) mutations (n = 5), whereas it appears excellent in patients with LRRK2 p.G2019S (c.6055G > A) mutations |
PRKN
| 18 | 67b | STN: n = 51 (76.1%) GPi: n = 5 (7.5%) Zona incerta: n = 1 (1.5%) NA: n = 10 (14.9%) | Fifty-one patients (76.1%) had favourable long-term motor outcomes. Four patients (6.0%) were reported to have modest outcome in two different studies and one study with two patients (3.0%) reported poor benefit |
GBA
| 5 | 50c | STN: n = 33 (66.0%) GPi: n = 4 (8.0%) VIM: n = 1 (2.0%) NA: n = 12 (24.0%) | Eighteen patients were reported to have favourable, three patients moderate and 9 patients poor long-term motor outcomes. One study reported better outcomes with STN-DBS and VIM-DBS than with GPi-DBS. GBA mutation carriers developed cognitive impairment faster than patients without mutations |
SNCA
| 5 | 5 | STN: n = 4 (80.0%) GPi: n = 1 (20.0%) | Favourable motor outcome but three of five patients developed cognitive or neuropsychiatric problems a few years after implantation |
VPS35
| 4 | 5 | STN: n = 3 (60.0%) NA: n = 2 (40.0%) | Favourable motor outcome in four cases and minor motor benefit complicated by dysarthria in one case |
PINK1
| 5 | 5b | STN: n = 4 (80.0%) GPi: n = 1 (20.0%) | Favourable motor outcome in three cases and moderate in one case |
22q11.2.Del. Syndrome
| 1 | 3 | STN: n = 1 (33.3%) GPi: n = 2 (66.6%) | Favourable motor outcome |